Issue 3, 2017

Synthesis and antitumor mechanism of a new iron(iii) complex with 5,7-dichloro-2-methyl-8-quinolinol as ligands

Abstract

A new iron(III) complex with 5,7-dichloro-2-methyl-8-quinolinol (HClMQ) as ligands, i.e., [Fe(ClMQ)2Cl] (1), was synthesized and evaluated for its anticancer activity. Compared to the HClMQ ligand, complex 1 showed a higher cytotoxicity towards a series of tumor cell lines, including Hep-G2, BEL-7404, NCI-H460, A549, and T-24, with IC50 values in the range of 5.04–14.35 μM. Notably, the Hep-G2 cell line was the most sensitive to complex 1. Mechanistic studies indicated that complex 1 is a telomerase inhibitor targeting c-myc G-quadruplex DNA and can trigger cell apoptosis via inducing cell cycle arrest and DNA damage.

Graphical abstract: Synthesis and antitumor mechanism of a new iron(iii) complex with 5,7-dichloro-2-methyl-8-quinolinol as ligands

Supplementary files

Article information

Article type
Research Article
Submitted
20 Nov 2016
Accepted
26 Jan 2017
First published
01 Feb 2017

Med. Chem. Commun., 2017,8, 633-639

Synthesis and antitumor mechanism of a new iron(III) complex with 5,7-dichloro-2-methyl-8-quinolinol as ligands

B. Zou, Q. Qin, Y. Bai, Q. Cao, Y. Zhang, Y. Liu, Z. Chen and H. Liang, Med. Chem. Commun., 2017, 8, 633 DOI: 10.1039/C6MD00644B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements